Terpenoids as promising therapeutic molecules against Alzheimer’s disease: amyloid beta- and acetylcholinesterase-directed pharmacokinetic and molecular docking analyses
Alzheimer’s disease (AD) is a progressive neurological disorder of brain encompassing deterioration of cognitive functions and behavioural changes eventually leading to cell death and dementia. Several attempts have been made to treat AD by the use of combined drug therapy against acetylcholinesterase (AChE) and amyloid beta (Aβ) simultaneously with the aim to delay its progress. However, side effects of long-term administration of these drugs have directed research towards development of a new generation of therapeutics based on natural compounds. In this regard, one hundred terpenoids were analysed for their inhibitory potential against AChE and Aβ through molecular docking approach. The selected terpenoids were further screened for their pharmacokinetic properties, among which only 25 terpenoids were found to fulfil all the ADMET descriptors and drug likeness properties which are essential for ensuring the development of safer drugs. A triterpene, nimbolide, was found to be the most potent and safe inhibitor for both AChE and Aβ as compared to their respective drugs/known inhibitors. The results of docking were further confirmed using molecular dynamics simulation analysis of complexes of nimbolide with both the targets. Thus, the present work makes a foundation for further clinical investigations of nimbolide as a drug against AD.
Publisher URL: http://www.tandfonline.com/doi/full/10.1080/08927022.2017.1334880
Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.
Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.